Aridis Pharma seeks $35M to fight infections with immunotherapies — latest in an IPO streak

Getting ready for its first Phase III trial, Aridis Pharma is now turning to public investors to support its pathogen-specific immunotherapies in a modest $35 million IPO.

Vu Truong

San Jose, CA-based Aridis joins an ever-growing crowd of biotechs looking to cash in on the bullish sentiment on display on Nasdaq. Their pitch: a portfolio of fully human monoclonal antibodies treat life-threatening infections such as hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP), developed from a proprietary discovery platform.

All three of Aridis’ clinical programs target HAP and VAP, differing only in the pathogen that they target. With lead asset AR-301, they are starting off with S. aureus.

Eric Patzer

AR-301 and another Phase II drug, AR-101 hitting P. aeruginosa, are the core assets of a joint venture Aridis set up a few months ago with Shenzhen Hepalink Pharmaceutical, investing $1 million — Hepalink chipped in the other $15 million — in which the Chinese partner would develop and seek approval for the drugs in the country.

Hepalink’s US subsidiary is a major stockholder of Aridis, commanding 17.8% of the stock, followed by founder and CEO Vu Truong at 15.1% and chairman Eric Patzer at 13.7%. Other investors include Pineworld Capital and Efung Ruibo. Notably, Robert Coughlin, president and CEO of MassBio, also holds less than 1% of the shares.

Other than directly funding the clinical trials, the biotech — to be listed as $ARDS — is also allocating part of the raise for the manufacturing of clinical supplies for use in the trials, according to the S-1.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 42,200+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Associate Principal, Life Sciences Partnerships
Flatiron Health New York City or San Francisco
Head of Business Development
Wren Therapeutics Boston, MA
Life Sciences Venture Professional
Northpond Ventures Washington, DC

Visit Endpoints Careers ->